Compare VOR & INNV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VOR | INNV |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2021 | 2021 |
| Metric | VOR | INNV |
|---|---|---|
| Price | $22.35 | $10.66 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 10 | 1 |
| Target Price | ★ $45.33 | $7.00 |
| AVG Volume (30 Days) | ★ 697.7K | 207.6K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 90.91 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $989,707,000.00 |
| Revenue This Year | N/A | $12.85 |
| Revenue Next Year | N/A | $8.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.93 |
| 52 Week Low | $6.50 | $3.94 |
| 52 Week High | $49.95 | $12.64 |
| Indicator | VOR | INNV |
|---|---|---|
| Relative Strength Index (RSI) | 47.59 | 43.64 |
| Support Level | $21.90 | $10.09 |
| Resistance Level | $24.44 | $10.69 |
| Average True Range (ATR) | 1.13 | 0.55 |
| MACD | -0.19 | -0.03 |
| Stochastic Oscillator | 12.44 | 12.69 |
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.